Your browser doesn't support javascript.
loading
Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients.
Silva, Bárbara de Oliveira; Medeiros, Jonathan Wagner; Albuquerque, Giwellington Silva; Valderrama, Pavel Medina; Barbosa, Athos Henrique de Quevedo; de Souza, Juliana Maria; Oliveira, Renata Santos; Morais, Adriana Lins; Neto, Jacinto da Costa Silva; Muniz, Maria Tereza Cartaxo.
Afiliación
  • Silva BO; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil; Universidade Federal de Pernambuco, Departamento de Bioquímica, Recife, PE, Brazil.
  • Medeiros JW; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil; Universidade Federal de Pernambuco, Departamento de Citopatologia, Recife, PE, Brazil.
  • Albuquerque GS; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil; Universidade Federal de Pernambuco, Departamento de Citopatologia, Recife, PE, Brazil.
  • Valderrama PM; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil.
  • Barbosa AHQ; Universidade Federal de Pernambuco, Departamento de Citopatologia, Recife, PE, Brazil.
  • de Souza JM; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil.
  • Oliveira RS; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil.
  • Morais AL; Universidade de Pernambuco, Centro de Oncohematologia Pediátrica do Hospital Universitário Oswaldo Cruz, Recife, PE, Brazil.
  • Neto JDCS; Universidade Federal de Pernambuco, Departamento de Citopatologia, Recife, PE, Brazil.
  • Muniz MTC; Universidade de Pernambuco, Instituto de Ciências Biológicas, Recife, PE, Brazil. Electronic address: tereza.cartaxo@upe.br.
J Pediatr (Rio J) ; 99(1): 59-64, 2023.
Article en En | MEDLINE | ID: mdl-35868407
OBJECTIVE: The aim of our study was to evaluate the expression of MMP-2 and MMP-9 as a prognostic factor in patients diagnosed with Hodgkin Lymphoma (HL). METHODS: In the present study, 45 paraffin biopsies from patients up to 19 years old diagnosed with HL were used in two referral hospitals in the state of Pernambuco, Brazil. Risk groups were classified into favorable and unfavorable, according to Ann Arbor. The expression of matrix metalloproteinases 2 and 9 and their inhibitors was performed by immunohistochemistry (IHC). Data were analyzed using the GraphPad Prism 5 program. RESULTS: MMP-2 intensity pattern was stronger (>10% of the total field) in patients with stage III/IV and B symptoms. MMP-2 showed an association with the risk group (p = 0.0388). That is, the stronger the MMP-2 marking, the greater the unfavorable risk. However, for MMP-9 there was no difference in the stronger intensity pattern in relation to stages I/II and III/IV, only in the presence of B symptoms. MMP-9 showed an association with B Symptoms (p = 0.0411). Therefore, patients with B symptoms have higher MMP-9 expression. CONCLUSION: Our results suggest that MMP-2 expression is associated with HL progression. While MMP-9 expression is related to the clinical worsening of these patients. However, further studies are needed to evaluate the exact role of these proteins in hematologic malignancies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Metaloproteinasa 2 de la Matriz / Metaloproteinasa 9 de la Matriz Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Pediatr (Rio J) Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Metaloproteinasa 2 de la Matriz / Metaloproteinasa 9 de la Matriz Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Pediatr (Rio J) Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Brasil